Global IgA Nephropathy Disease Treatment Market, By Test ; By Treatment ; By Region ; Trend Analysis, Competitive Market Share & Forecast, 2018-2028

PUBLISHED: August 5, 2022

PAGES: 240 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

IgA Nephropathy Disease Treatment Market to Surpass USD 485 Million by 2028

The growth of the IgA nephropathy disease treatment market can be primarily attributed to the escalation in demand for the treatment owing to rising renal disease burden throughout the world. Moreover, the increasing investment in research, development and healthcare infrastructure is further expected to drive the global IgA Nephropathy disease treatment market during the forecast period.

A recent study by the strategic consulting and market research firm; Blue Weave Consulting revealed that the Global IgA Nephropathy Disease Treatment Market was worth USD 130 million in 2021 and is projected to reach USD 485.6 million by the year 2028, growing at a CAGR of 20.8% during the period of 2022-2028. The growth of the IgA nephropathy disease treatment market can be primarily attributed to the escalation in demand for the treatment owing to the rising global renal disease burden. Moreover, the increasing investment in research, development, and healthcare infrastructure is further expected to drive the global IgA Nephropathy disease treatment market during the forecast period.

Increasing Investment for Ramping Up Healthcare Infrastructure Driving Global IgA Nephropathy Disease Treatment Market Growth

One of the most significant factors influencing the growth rate of the immunoglobulin A (IgA) nephropathy disease treatment market is the surge in healthcare expenditure, which helps in enhancing its infrastructure. Also, several government organizations aim to advance the healthcare infrastructure by augmenting funding which is further expected to influence the market dynamics of the IgA Nephropathy disease treatment market. Additionally, the increment in the number of government initiatives to spread awareness and snowball the geriatric population is likely to result in the expansion of the immunoglobulin A (IgA) nephropathy market over the forecast period. In addition, the growing level of disposable income coupled with a sedentary lifestyle as a direct consequence of fast-paced urbanization is likely to further enhance the market's growth rate over the forecast period.

Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors) And Angiotensin-Receptor Blockers (Arbs) Segment Account for The Largest Market Share In 2021

Based on treatment type, the global IgA Nephropathy Disease Treatment market has been segmented into Corticosteroids, Immunosuppressive Drugs, ACE Inhibitors and ARBs, Diet Change and Therapy. The IgA Nephropathy disease treatment doesn't have any particular medication for the condition; thus, various medications and sometimes a combination of them is used for the cure of the disease. Amidst the segmentation, Angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin-receptor blockers (ARBs) are two of the most used IgA Nephropathy therapies. Angiotensin-converting enzyme (ACE) inhibitors are medicines that aid in relaxing the arteries and veins to decrease blood pressure. ACE inhibitors avert an enzyme in the body from synthesizing angiotensin II, a substance that constricts the blood vessels. Angiotensin receptor blockers (ARBs) are used for treating chronic kidney disease and are often prescribed following a heart attack or high blood pressure.

The Asia-Pacific Region Is Expected To Grow with The Highest CAGR In The Global IgA Nephropathy Disease Treatment Market.

Regarding regional analysis, the global IgA Nephropathy Disease Treatment market has been classified into North America, Europe, the Asia-Pacific, Latin America and the Middle East, and Africa. Amidst the segmentation, the Asia-Pacific region is expected to be the fastest growing market in the region during the forecast period. This can be attributed to the rising demand for IgA Nephropathy Disease Treatment due to the increase in disease in patients and the worsening of patients' health. Likewise, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region. Moreover, the existence of chief companies, including Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, and Lupin, offer attractive market growth opportunities, thus bolstering the growth of the IgA Nephropathy Disease Treatment market in the Asia-Pacific region during the forecast period.

Impact Of COVID-19 On the Global IgA Nephropathy Disease Treatment Market

Due to the abrupt outbreak of the COVID-19 pandemic, patient movement and probable identification were substantially restricted due to the stringent lockdown measures implemented throughout the world. The healthcare institutions were overburdened with the influx of a large number of COVID-19 cases, thus impacting the availability of treatment for other health situations. Patients undergoing certain treatments experienced a remarkably long turnaround time due to the COVID 19 outbreak. Patients suffering from kidney disease at any stage and kidney transplant receivers did not have much protection against COVID-19 even if they were completely vaccinated. Moreover, a flash of immune-mediated disease succeeding coronavirus immunization (COVID-19) vaccination was reported, which is quite a rare adverse event following immunization. Relapsing IgA nephropathy (IgAN) cases were reported following either after BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccinations.

Competitive Landscape

The global IgA Nephropathy Disease Treatment market is characterized by many local, regional, and international vendors. The key players operating in the global IgA Nephropathy Disease Treatment market are AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., Siemens Healthcare GmbH, Zydus Cadila, Hikma Pharmaceuticals PLC, LEO Pharma A/S, Fresenius Kabi AG, Accord Healthcare, Abbott, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, Alembic Pharmaceuticals Limited, Apotex Inc. and other prominent players. The players maintain their dominance in the market by investing in research and development activities and integrating the latest and most advanced technologies into their products.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the global IgA Nephropathy Disease Treatment market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the global IgA Nephropathy disease treatment market ¬along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the market's growth drivers, challenges, and competitive dynamics.

Product Code: BWC22262

1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Research Methodology

2.1. Qualitative Research
- 2.1.1. Primary & Secondary Research
2.2. Quantitative Research
2.3. Market Breakdown & Data Triangulation
- 2.3.1. Secondary Research
- 2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Region
2.5. Assumption & Limitation

3. Executive Summary

4. Global IgA Nephropathy Disease Treatment Market Insights

4.1. Industry Value Chain Analysis
4.2. DROC Analysis
- 4.2.1. Growth Drivers
- 4.2.2. Restraints
- 4.2.3. Opportunities
- 4.2.4. Challenges
4.3. Technological Advancement/Recent Development
4.4. Regulatory Framework
4.5. Porter's Five Forces Analysis
- 4.5.1. Bargaining Power of Suppliers
- 4.5.2. Bargaining Power of Buyers
- 4.5.3. Threat of New Entrants
- 4.5.4. Threat of Substitutes
- 4.5.5. Intensity of Rivalry

5. Global IgA Nephropathy Disease Treatment Market Overview

5.1. Market Size & Forecast by Value, 2018-2028
- 5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
- 5.2.1. By Test
  - 5.2.1.1. Blood Test
  - 5.2.1.2. Urine Test
  - 5.2.1.3. Kidney Biopsy
  - 5.2.1.4. Iothalamate Clearance Test
  - 5.2.1.5. Others
- 5.2.2. By Treatment
  - 5.2.2.1. Corticosteroids
  - 5.2.2.2. Immunosuppressive Drugs
  - 5.2.2.3. ACE Inhibitors and ARBs
  - 5.2.2.4. Diet Change
  - 5.2.2.5. Therapy
- 5.2.3. By Region
  - 5.2.3.1. North America
  - 5.2.3.2. Europe
  - 5.2.3.3. The Asia Pacific
  - 5.2.3.4. Latin America
  - 5.2.3.5. The Middle East and Africa

6. North America IgA Nephropathy Disease Treatment Market

6.1. Market Size & Forecast by Value, 2018-2028
- 6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
- 6.2.1. By Test
- 6.2.2. By Treatment
- 6.2.3. By Country
  - 6.2.3.1. United States
  - 6.2.3.2. Canada

7. Europe IgA Nephropathy Disease Treatment Market

7.1. Market Size & Forecast by Value, 2018-2028
- 7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
- 7.2.1. By Test
- 7.2.2. By Treatment
- 7.2.3. By Country
  - 7.2.3.1. Germany
  - 7.2.3.2. United Kingdom
  - 7.2.3.3. Italy
  - 7.2.3.4. France
  - 7.2.3.5. Spain
  - 7.2.3.6. Rest of Europe

8. The Asia Pacific IgA Nephropathy Disease Treatment Market

8.1. Market Size & Forecast by Value, 2018-2028
- 8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
- 8.2.1. By Test
- 8.2.2. By Treatment
- 8.2.3. By Country
  - 8.2.3.1. China
  - 8.2.3.2. India
  - 8.2.3.3. Japan
  - 8.2.3.4. South Korea
  - 8.2.3.5. Rest of Asia Pacific

9. Latin America IgA Nephropathy Disease Treatment Market

9.1. Market Size & Forecast by Value, 2018-2028
- 9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
- 9.2.1. By Test
- 9.2.2. By Treatment
- 9.2.3. By Country
  - 9.2.3.1. Brazil
  - 9.2.3.2. Mexico
  - 9.2.3.3. Rest of Latin America

10. The Middle East & Africa IgA Nephropathy Disease Treatment Market

10.1. Market Size & Forecast by Value, 2018-2028
- 10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
- 10.2.1. By Test
- 10.2.2. By Treatment
- 10.2.3. By Country
  - 10.2.3.1. Saudi Arabia
  - 10.2.3.2. UAE
  - 10.2.3.3. South Africa
  - 10.2.3.4. Rest of Middle East & Africa

11. Competitive Landscape

11.1. List of Key Players and Their Offerings
11.2. Market Share Analysis, 2021
11.3. Competitive Benchmarking, By Operating Parameters
11.4. Key Strategic Development (Merger, Acquisition, Partnership.)

12. Supplier Analysis

13. Impact of Covid-19 on Global IgA Nephropathy Disease Treatment Industry

14. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **

14.1. AstraZeneca
14.2. Johnson & Johnson Private Limited
14.3. Cipla Inc.
14.4. Siemens Healthcare GmbH
14.5. Zydus Cadila
14.6. Hikma Pharmaceuticals PLC
14.7. LEO Pharma A/S
14.8. Fresenius Kabi AG
14.9. Accord Healthcare
14.10. Abbott
14.11. F. Hoffmann-La Roche Ltd.
14.12. Mylan N.V.
14.13. Teva Pharmaceutical Industries Ltd.
14.14. Sanofi
14.15. Novartis AG
14.16. Sun Pharmaceutical Industries Ltd.
14.17. Aurobindo Pharma
14.18. Lupin
14.19. Alembic Pharmaceuticals Limited
14.20. Apotex Inc
14.21. Other Prominent Players

15. Key Strategic Recommendations

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List Of Figures

Figure 1: Global IgA Nephropathy Disease Treatments Market Segmentation
Figure 2: Global IgA Nephropathy Disease Treatment Industry Value Chain Analysis
Figure 3: Global IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028
Figure 4: Global IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028
Figure 5: Global IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028
Figure 6: Global IgA Nephropathy Disease Treatment Market Share (%), By Region, By Value, 2018-2028
Figure 7: North America IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028
Figure 8: North America IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028
Figure 9: North America IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028
Figure 10: North America IgA Nephropathy Disease Treatment Market Share (%), By Country, By Value, 2018-2028
Figure 11: Europe IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028
Figure 12: Europe IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028
Figure 13: Europe IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028
Figure 14: Europe IgA Nephropathy Disease Treatment Market Share (%), By Country, By Value, 2018-2028
Figure 15: The Asia-Pacific IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028
Figure 16: The Asia-Pacific IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028
Figure 17: The Asia-Pacific IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028
Figure 18: The Asia-Pacific IgA Nephropathy Disease Treatment Market Share (%), By Country, By Value, 2018-2028
Figure 19: Latin America IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028
Figure 20: Latin America IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028
Figure 21: Latin America IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028
Figure 22: Latin America IgA Nephropathy Disease Treatment Market Share (%), By Country, By Value, 2018-2028
Figure 23: The Middle East & Africa IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028
Figure 24: The Middle East & Africa IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028
Figure 25: The Middle East & Africa IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028
Figure 26: The Middle East & Africa IgA Nephropathy Disease Treatment Market Share (%), By Country, By Value, 2018-2028
Figure 27: Global IgA Nephropathy Disease Treatment Market Share Analysis, 2021

List Of Tables

Table 1: Global IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028
Table 2: Global IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028
Table 3: Global IgA Nephropathy Disease Treatment Market Size. By Region, By Value (USD Million), 2018-2028
Table 4: North America IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028
Table 5: North America IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028
Table 6: 28 North America IgA Nephropathy Disease Treatment Market Size (USD Million), By Country, By Value 2018-2028
Table 7: Europe IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028
Table 8: Europe IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028
Table 9: Europe IgA Nephropathy Disease Treatment Market Size (USD Million), By Country, By Value 2018-2028
Table 10: The Asia-Pacific IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028
Table 11: The Asia-Pacific IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028
Table 12: 52 The Asia-Pacific IgA Nephropathy Disease Treatment Market Size (USD Million), By Country, By Value 2018-2028
Table 13: Latin America IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028
Table 14: Latin America IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028
Table 15: Latin America IgA Nephropathy Disease Treatment Market Size (USD Million), By Country, By Value 2018-2028
Table 16: The Middle East & Africa IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028
Table 17: The Middle East & Africa IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028
Table 18: 76 The Middle East & Africa IgA Nephropathy Disease Treatment Market Size (USD Million), By Country, By Value 2018-2028
Table 19: List of Key Players and Their Offerings
Table 20: Competitive Benchmarking, by Operating Parameters
Table 21 AstraZeneca Company Overview
Table 22 AstraZeneca Financial Overview
Table 23 Johnson & Johnson Private Limited Company Overview
Table 24 Johnson & Johnson Private Limited Financial Overview
Table 25 Siemens Healthcare GmbH Company Overview
Table 26 Siemens Healthcare GmbH Financial Overview
Table 27 Zydus Cadila Company Overview
Table 28 Zydus Cadila Financial Overview
Table 29 LEO Pharma A/S Company Overview
Table 30 LEO Pharma A/S Financial Overview
Table 31 Accord Healthcare Company Overview
Table 32 Accord Healthcare Financial Overview
Table 33 Abbott Company Overview
Table 34 Abbott Financial Overview
Table 35 F. Hoffmann-La Roche Ltd. Company Overview
Table 36 F. Hoffmann-La Roche Ltd. Financial Overview
Table 37 Mylan N.V. Company Overview
Table 38 Mylan N.V. Financial Overview
Table 39 Teva Pharmaceutical Industries Ltd. Company Overview
Table 40 Teva Pharmaceutical Industries Ltd. Financial Overview
Table 41 Sanofi Company Overview
Table 42 Sanofi Financial Overview
Table 43 Novartis AG Company Overview
Table 44 Novartis AG Financial Overview
Table 45 Sun Pharmaceutical Industries Ltd. Company Overview
Table 46 Sun Pharmaceutical Industries Ltd. Financial Overview
Table 47 Aurobindo Pharma Company Overview
Table 48 Aurobindo Pharma Financial Overview
Table 49 Lupin Company Overview
Table 50 Lupin Financial Overview